A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice
NCT05443568 · Completed
Last updated 2026-05-28This study is observing how the medication semaglutide, taken by mouth, affects blood sugar levels in adults with type 2 diabetes in Israel as part of their regular medical care.
What this study is testing ClinicalTrials.gov NCT05443568 ↗
Description as written by the study sponsor.
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels. Participants will get Rybelsus® as prescribed to them by the study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor.
Treatments tested
- Oral semaglutide Drug
Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
| Main thing measured | Change in HbA1c (Glycated haemoglobin) |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Conditions studied | Diabetes Mellitus, Type 2 |
| GLP-1 drugs | semaglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05443568 ↗